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Oxcarbazepine (OXC) is an important anticonvulsant and mood stabilizing drug. A pharmacopoeial 
monograph for OXC is not yet available and therefore the development and validation of a new analytical 
method for quantification of this drug is essential. In the present study, a UV spectrophotometric method 
for the determination of OXC was developed. The various parameters, such as linearity, precision, 
accuracy and specificity, were studied according to International Conference on Harmonization Guidelines. 
Batches of 150 mg OXC capsules were prepared and analyzed using the validated UV method. The 
formulations were also evaluated for parameters including drug-excipient compatibility, flowability, 
uniformity of weight, disintegration time, assay, uniformity of content and the amount of drug dissolved 
during the first hour.
Uniterms: Oxcarbazepine/quantitative analysis. Anticonvulsants/quantitative analysis. UV 
spectrophotometric/method validation. Capsules/dissolution.
Oxcarbazepina (OXC) é um fármaco anticonvulsivante e estabilizante do humor. O desenvolvimento 
e validação de método analítico para quantificação da OXC são de fundamental importância devido 
à ausência de monografias farmacopéicas oficiais para esse fármaco. Nesse trabalho, um método 
espectrofotométrico UV para determinação da OXC foi desenvolvido. O método proposto foi validado 
seguindo os parâmetros de linearidade, precisão, exatidão e especificidade de acordo com as normas da 
Conferência Internacional de Harmonização. Cápsulas de OXC 150 mg foram preparadas e analisadas 
utilizando-se o método analítico validado. As formulações foram avaliadas com relação à compatibilidade 
fármaco-excipientes, fluidez, determinação de peso, tempo de desintegração, doseamento, uniformidade 
de conteúdo e quantidade do fármaco dissolvido após 60 minutos. 
Unitermos: Oxcarbazepina/análise quantitativa. Anticonvulsivante/análise quantitativa. 
Espectrofotometria UV/validação do método. Cápsulas manipuladas/dissolução.
INTRODUCTION
Oxcarbazepine (OXC) is a keto analog of carbama-
zepine (CBZ) and is an important anticonvulsant and mood 
stabilizing drug. The exact mechanism of action of OXC 
is unknown, although it is believed to involve blockade of 
voltage-gated sodium channels (Kalis, Huff, 2001). It is 
quickly absorbed after oral administration and undergoes 
rapid and almost complete reductive metabolism to form 
the pharmacologically active 10-monohydroxy derivative 
(MHD) (Shorvon, 2000) (Figure 1).
Since OXC and its pharmaceutical formulations have not yet been listed in any of the Pharmacopoeias, an 
analytical method needs to be developed for the quality 
control of the product.
Several high-performance liquid chromatographic 
(HPLC) methods have been reported in the literature for 
FIGURE 1 - Chemical structure of carbamazepine, oxcarbazepine 
and 10-monohydroxy derivative. 
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the determination of OXC (Pathare et al., 2007; Qi et al., 
2003). To the best of our knowledge, one spectrophoto-
metric method has been reported for the analysis of this 
drug in the literature, based on the reduction of ferric 
ions in their salt form to ferrous ions by the drug (Ramaa 
et al., 2006). The HPLC method is widely employed in 
quality control assessment of drugs because of its sensiti-
vity, repeatability and specificity. On the other hand, the 
use of spectroscopic techniques is a promising simple, 
faster, direct and relatively lower cost alternative for the 
determination of active drug content in pharmaceutical 
formulations which provides sufficient reliability. Hence, 
we developed a simple UV spectrophotometric method 
to determine OXC in pharmaceutical dosage forms. The 
method fulfilled the requirements of analytical quality 
necessary to be applied to the assay and content uniformity 
tests indicated by Brazilian Pharmacopoeia (1988) for 
finished pharmaceutical products when these are present 
as single active principles, and hence can be successfully 
applied for routine quality control of tablets or capsules. 
MATERIALS AND METHODS 
Material
Oxcarbazepine was generously donated by the 
Cristália pharmaceutical company (Brazil). Pregelatinized 
starch and microcrystalline cellulose were a generous gift 
from Colorcon (Brazil). Corn starch and sodium lauryl 
sulfate were purchased from Pharmacopéia – Attivos 
Magisttrais (São Paulo, Brazil). Magnesium stearate and 
lactose monohydrate were obtained from Ipiranga Quími-
ca (São Paulo, Brazil). Talc was provided by Proquímios 
Comércio e Indústria Ltda (Rio de Janeiro, Brazil) and 
aerosil and mannitol from Henrifarma Produtos Químicos 
e Farmacêuticos Ltda (São Paulo, Brazil). High purity 
water was prepared by using a Milli-Q water purification 
system from Millipore. All other materials and solvents 
were of analytical reagent grade.
Validation of UV spectrophotometric method
The UV spectrophotometric method was performed 
at 305 nm. Linearity: the calibration curve was obtai-
ned with nine concentrations of the standard solution 
(10-90 µg/mL). The solutions were prepared in tripli-
cate. The linearity was evaluated by least-squares linear 
regression analysis and correlation coefficients were 
calculated (Excel®). Precision: the precision of the assay 
method was determined by repeatability (intra-day) and 
intermediate precision (inter-day). The intra-day preci-
sion was evaluated by analyzing six samples at 100% 
(50 μg/mL) of the test concentration (n = 6). Similarly, 
the intermediate precision was evaluated on two con-
secutive days (n = 12). The concentration of OXC was 
determined and the value of relative standard deviation 
(%R.S.D) of the assay method was calculated. Accuracy: 
accuracy was determined by spiking known amounts of 
the analyte into the placebo formulation (F1, F2 and F3) 
across the specified range of the analytical procedure to 
obtain 40, 50 and 60 µg/ml (80, 100 and 120%). At each 
level, solutions were prepared in triplicate and the accu-
racy was evaluated in terms of percent recovery. Percent 
Recovery was calculated using the formula [%Recovery 
= 100 x Mean Experimental Concentration/ Theoretical 
Concentration]. Selectivity: the method selectivity was 
assessed by comparing UV spectrum obtained from the 
OXC with those obtained from placebo formulations (ex-
cipients solution in methanol without OXC). Robustness: 
three sample solutions were prepared each containing 
50 µg/mL, and analyzed in two different UV-visible spec-
trophotometers (Hewlett Packard 8453 and Shimadzu 
160A) immediately after the preparation of the solutions. 
The data obtained was submitted to statistical analysis 
(Student’s t test) at a significance level of 0.05. Detection 
and quantification limits: detection and quantification 
limits were determined based on the standard deviation of 
the response (σ) and the slope (S) of the calibration curve 
of the analyte. The detection limit may be expressed as 
3.3(σ/ S) and the quantification limit may be expressed 
as 10(σ/ S) (ICH, 1996).
Development of capsule formulations
Differential scanning calorimetry (DSC)
Compatibilities of several commonly used pharma-
ceutical excipients with OXC were evaluated using the 
Differential Scanning Calorimetry (DSC) technique. DSC 
thermograms of the drug alone, each excipient alone, and 
drug-excipient physical mixtures (1:1 w/w) were derived 
from a DSC (TA-2910, TA-instruments). The instrument 
was calibrated with an indium standard. The compounds 
were ground for 5 min using a pestle and mortar. The po-
wders obtained were slightly compacted in the aluminium 
pan by a steel plunger to achieve a uniform powder bed 
in contact with the pan bottom. The samples (2-4 mg) 
were heated (25-250 °C) at a constant scanning speed 
(10 °C/min), using nitrogen as the purging gas. 
Capsule formulations
The formulations used in this study are shown in 
Table I. 
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TABLE I - Formulations of 150 mg OXC Capsules 
Ingredient Formulation 1 
(%)
Formulation 2 
(%)
Formulation 3 
(%)
Class
Oxcarbazepine 40.5 43 34.9 Active
Microcel MC-101, microcrystalline cellulose 34 - - Diluent, disintegrant
Corn starch 19 - - Diluent, disintegrant
Lactose monohydrate, USP - - 48.4 Diluent
Mannitol - - 14.7 Diluent
Starcap 1500, pregelatinized corn starch - 57 - Diluent, disintegrant
Talc 4.5 - - Lubricant
Magnesium stearate 0.5 - - Lubricant
Aerosil 0.5 - 0.9 Glidant
Sodium lauryl sulfate 1 - 1.1 Surfactant
Total 100 100 100
Flow properties 
Densities of bulk were examined as suggested by the 
British Pharmacopoeia’s Technical Procedure “Apparent 
Volume” (British Pharmacopoeia, 2008) using an Erweka 
SVM volumeter. Deviating from the instructions, a 100 ml 
graduated cylinder was used for better accuracy in reading 
volumes. The cylinder was filled with 25-35 g of OXC or ex-
cipients only (Sartorius 2482 balance, accuracy ± 0.1 mg). 
The initial volume was measured and poured densities 
calculated. After 1250 taps the corresponding volume was 
read to the nearest milliliter. V
1250
 was used to calculate 
tapped density. The bulk and tapped densities were also 
determined for each formulation (drug + excipients). 
From the bulk and tapped densities, Carr’s index 
(CI) (Carr, 1965) was calculated for each formulation, 
using the following equation:
 
Capsule preparation
Micronized OXC and excipients were weighed, 
passed through a 16 mesh sieve and mixed for 5 minutes in 
a porcelain mortar and pestle. Magnesium stearate and/or 
aerosil were then added to each mixture, and the mixture 
was blended for 1 additional minute. The typical batch size 
was 100 capsules. All batches were prepared according to 
uniform procedures. All hard gelatin capsules were size 0. 
The dose of OXC was 150 mg/capsule. A manual filling 
machine was used. 
Physicochemical analyses of capsules
Uniformity of weight and disintegration time were 
evaluated according to the methodologies described in the 
British Pharmacopoeia (2008) and Brazilian Pharmaco-
poeia (1988), respectively.
Assay and uniformity of content of capsules
Quantitative analyses were carried out using the 
UV spectrophotometric method validated as described in 
the item “Validation of UV spectrophotometric method”. 
Assay and content uniformity testing were performed for 
all formulations tested. Assay: twenty capsules were ran-
domly selected and the quantity of powder equivalent to 
100 mg of OXC was dissolved in methanol, transferred to 
a 100 mL volumetric flask, and the volume completed with 
the same solvent. Content uniformity testing: ten capsules 
were randomly selected and individually assayed for OXC 
amount. The concentration of each batch was determined 
from the calibration curve previously obtained for a pure 
sample of OXC. 
Dissolution
The amount of drug dissolved in 60 min was de-
termined to evaluate the performance of the manipulated 
capsules and the influence of excipients on drug release. 
An experimental plan was developed to evaluate the in-
fluence of dissolution medium and stirring speed on the 
drug release behavior of each formulation. The dissolution 
conditions were: 900 ml of water with 0.5 and 1.0% w/v of 
sodium lauryl sulphate (SLS) as dissolution medium, using 
a basket apparatus at a stirring speed of 75 and 100 rpm. 
The mediums were maintained at 37 ± 0.5 ºC. Sampling 
aliquots of 10 ml were withdrawn at 30 and 60 minutes 
after placing the capsules in the dissolution medium. The 
drug release was evaluated by the UV spectrophotometric 
method at 305 nm. The drug release percent was obtained 
by comparing the absorbance found after diluting the 
dissolution test aliquots with the absorbance of 100% 
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theoretical dissolution concentration, while the dissolution 
profiles were obtained by plotting average percentage of 
drug release versus time.
The interference of SLS of the dissolution medium 
on the quantitative step of the dissolution profile was 
evaluated. The spectrum of the standard solutions of 
OXC 50.00 μg/mL (blank determination with SLS at the 
concentrations of 0.5% and 1.0%) and the spectrum of the 
solutions containing 0.5 and 1.0% SLS (blank determina-
tion with water) were superimposed. 
The linearity was evaluated by linear regression 
analysis, which was calculated by the least squares regres-
sion method. After the end of the test time, each sample 
aliquot was diluted to a suitable concentration to reach 
optimal absorption measurement of about 0.5 absorbance 
units. Data were analyzed using ANOVA and Tukey’s tests.
RESULTS AND DISCUSSION
Validation of UV spectrophotometric method
The proposed UV method allows rapid and eco-
nomical quantitation of OXC in capsules without any 
time-consuming sample preparation. Moreover, the spec-
trophotometric methods involve simple instrumentation 
compared with other instrument techniques. The stock 
solutions and working standards were made in methanol. 
The λmax of the drug for analysis was determined by 
taking scans of the drug sample solutions in the entire UV 
region (200-400 nm). The wavelength 305 nm was then 
used for all measurements.
L i n e a r i t y :  t h e  m e t h o d  d e m o n s t r a -
ted to be l inear,  with a  correlat ion coeff icient 
of the standard curve greater than 0.999. The line-
ar regression equation was y = 10.125x – 0.0092. 
Beer’s law is obeyed over this concentration range. 
Precision: in the intra-day precision analysis (n = 6), 
the mean OXC content in the F1, F2 and F3 formulations 
were 98.98% (R.S.D. = 1.19%), 95.98% (R.S.D. = 1.18%) 
and 100.47% (R.S.D. = 1.03%), respectively. The values 
found in the inter-day precision (n = 12) were 98.89% 
(R.S.D. = 0.87%), 95.75% (R.S.D. = 0.91%) and 100.48% 
(R.S.D. = 1.25%) for the formulations F1, F2 and F3, 
respectively. The R.S.D (%) values obtained of less than 
2.0%, attested to the precision of the method.
Accuracy: the mean recovery (n = 9) of OXC 
from the F1, F2 and F3 formulations were 100.38% 
(R.S.D. = 0.92%), 100.04% (R.S.D. = 0.69%) and 99.60% 
(R.S.D. = 0.79%), respectively. These results indicate the 
accuracy of the proposed method for the determination 
of OXC.
Selectivity: placebo samples showed no interference 
in absorbance at 305 nm. These results demonstrate the 
good selectivity of the method.
Robustness: the mean absorbances measured using 
two different spectrophotometer models (Hewlett Packard 
8453 and Shimadzu 160A) were 0.504 and 0.499, respec-
tively. The experimental t value (2.69) was lower than the 
table value (2.78), indicating there was no significant diffe-
rence between the results from the two spectrophotometers.
Detection and quantification limits: the limit of 
detection of OXC achieved was 0.62 µg/mL. The limit of 
quantification achieved with this method was 1.88 µg/mL.
All the method validation parameters were well 
within the limits specified in the ICH Q2R1 guidelines 
(1996). A summary of results is shown in Table II.
Development of capsule formulations
Differential scanning calorimetry (DSC)
Interactions in the solid state among the active ingre-
dient and excipients in pharmaceutical dosage forms can 
give rise to changes in the stability, solubility, dissolution 
rate and bioavailability of drugs. Therefore, it would be 
extremely useful in the development of new pharmaceu-
tical formulations to have readily available knowledge 
about potential physical and chemical interactions between 
drugs and excipients. Differential scanning calorimetry 
(DSC) has shown to be a powerful tool in the first step of 
preformulation studies for investigating and predicting 
physicochemical incompatibility between a drug and phar-
maceutical excipients (Giron, 2002). DSC compatibility 
studies were carried out by comparing the thermal curve 
of pure OXC with the curves obtained from pure OXC at 
1:1 w/w individual mixtures with each excipient under 
consideration. 
The DSC curve of OXC was typical of a pure crys-
talline substance, showing a sharp endothermic peak at its 
melting point, with an onset temperature of 221.13 ºC. No 
significant degradation was seen to occur before 240 ºC. 
The melting temperature determined from the DSC curve 
was in accordance with that described in the literature, 
219-221 ºC (Carril et al., 2005). 
OXC was found to be compatible with microcrys-
talline cellulose, starch and talc. Interaction between 
OXC and mannitol, monohydrate lactose, colloidal silica, 
magnesium stearate and sodium lauryl sulfate (SLS) was 
observed and the extent of interaction varied from only a 
shift in the OXC melting endotherm to total abolition of 
the peak (Table III). The absence of the melting endotherm 
of OXC from the mixture with SLS may be due to the 
dissolution of the drug in the melting of the SLS. 
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TABLE II - Validation parameters for UV method of analysis of OXC
Parameters
Acceptance 
criteria
Results
OXC F1 F2 F3
Selectivity
Evaluated 
the ability of 
the proposed 
method to 
discriminate OXC 
from placebo 
formulations
-
No interferences 
from the 
excipients
No interferences 
from the 
excipients
No interferences 
from the 
excipients
Linearity r* > 0.999 0.9997 - - -
Precision
Intra-day R.S.D.** < 2% 0.61% 1.19% 1.18% 1.03%
Inter-day R.S.D.** < 2% 0.67% 0.87% 0.91% 1.25%
Accuracy 
(% Recovery)
80%
98-102% ---
100.05% 102.08% 100.51%
100% 100.91% 101.45% 99.18%
120% 100.17% 100.22% 99.10%
*Correlation coefficient. **R.S.D. = Relative Standard Deviation
Although some excipients were found to interact 
with OXC, one cannot conclusively state this incompatibi-
lity will be encountered upon storage at room temperature. 
These results suggest that Formulation 2 was the best for-
mulation among those studied (OXC is fully compatible 
with starch). Despite a possible incompatibility between 
OXC and some excipients of Formulations 1 and 3, these 
formulations were prepared in order to evaluate the effect 
of commonly used excipients on the extent and/or rate 
of drug release. It is noteworthy that these excipients are 
present in OXC tablets available in the pharmaceutical 
market.
Flow properties 
Poured densities of the OXC and formulations (Ta-
TABLE III – DSC data on drug and excipients
Sample Melting endotherm 
onset (ºC)
OXC 221.13
OXC/ microcrystalline cellulose 223.66
OXC/starch 218.81
OXC/talc 224.50
OXC/sodium lauryl sulfate -
OXC/mannitol 208.63
OXC/ colloidal silica 206.11
OXC/lactose 199.40
OXC/ magnesium stearate 206.64
ble IV) ranged from 0.38 g/mL (OXC) to 0.49 g/mL (For-
mulation 3), and tapped densities from 0.49 g/mL (OXC) 
to 0.64 g/mL (Formulation 3). The values of the calculated 
CI (Table IV) ranged from 14.8 (Formulation 1) to 25.0 
(Formulation 2). A CI below 15% is considered to be an 
indication of good flowability and thus Formulation 1 had 
excellent flowability. Formulations 2 and 3 had a CI above 
15%, which is regarded to represent the threshold between 
free flow (<15%) and no flow (>25%). 
Physicochemical analyses of capsules
Initially, the physicochemical characteristics of the 
capsules were evaluated. The summary of the uniformity 
of weight and disintegration time is shown in Table V.
Mean weight, obtained from individual weights 
of 20 capsules, yielded information about the variations 
in weight in capsules from the same batch, constituting 
one of the parameters which could influence the active 
uniformity of content among different capsules. Determi-
nation of disintegration time evaluates the time necessary 
for the release of OXC from the capsule. The OXC must 
be released from the capsule as efficiently as possible to 
allow for its rapid dissolution. If a pharmaceutical agent 
is released from the capsule slowly it cannot have a rapid 
dissolution rate whereas if disintegration is rapid then 
rapid dissolution is possible. 
All samples presented a weight variation of less than 
7.5% (British Pharmacopoeia, 2008) and a disintegration 
time (6-10 min) of less than 45 minutes (Brazilian Pharma-
copoeia, 1988). Therefore, the results presented in Table V 
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Table IV - Results of density measurements
Drug and 
Formulations
Sample mass 
(g)
Bulk volume 
(mL)
Tapped volume 
(mL)
Bulk density 
(g/mL)
Tapped density 
(g/mL)
Carr index 
(%)
OXC 25.35 66 51.5 0.3841 0.4922 22.0
Formulation 1 29.01 61 52 0.4756 0.5579 14.8
Formulation 2 29.85 64 48 0.4664 0.6219 25.0
Formulation 3 30.00 61 47 0.4918 0.6383 22.9
TABLE V – Physicochemical analyses of different formulations of OXC capsules
Formulations Mean weight (N= 20) Disintegration time (min) (N=6)
Maximum deviation Minimum deviation
1 4.93 -5.51 10
2 5.95 -2.87 10
3 5.67 -3.99 6
Limits Max. 7.5% Max. 45 min
showed that all evaluated formulations were in accordance 
with the official specifications. 
Assay and uniformity of content of capsules
Subsequently the active substance was assayed and 
uniformity of content in the capsule samples was deter-
mined. The results of the drug assay and uniformity of 
content are shown in Table VI.
The drug assay is a test to compare the theoreti-
cal quantitative contents of active substances in dosage 
forms (declared value) with the real values, determined 
experimentally by their quantification using established 
and validated methods. There is no Pharmacopeia mo-
nograph establishing acceptance criteria for the assay 
of OXC. Therefore, we consider the commonly accepted 
limit of 92-108% of the label claim (specified limit for the 
carbamazepine). The analysis of the uniformity of content 
evaluates the drug dose variation among each unitary 
TABLE VI - Assay and uniformity of content of different formulations of OXC capsules
Formulations Assay ± CI* 
(%) (N=5)
Uniformity of content (%) (N= 10)
Higher Lower R.S.D.** (%)
1 99.24 + 1.47 104.20 93.82 3.65
2 92.58 + 0.86 98.12 89.16 2.91
3 99.50 + 0.63 100.86 90.31 3.13
Limits 92-108% 85-115% 
RSD** (%): ≤ 6.0
*CI = Confidence interval 0.95. ** R.S.D. = Relative Standard Deviation
dosage form from the same batch.
Regarding the evaluation of the samples assay and 
its relation to the respective chemical reference substances, 
Formulations 1, 2 and 3 showed a drug content between 
92% and 108% of the declared value for the active substan-
ce. In relation to the uniformity of content test, all samples 
met the general specification for capsules (85%-115%, 
RSD ≤ 6.0%) (Brazilian Pharmacopoeia, 1996).
Dissolution 
The UV spectrophotometric method may be used 
for quantifying drug release in dissolution tests if the drug 
has a UV chromophore and no interference from formu-
lation excipients or dissolution medium components are 
observed. Based on our results it is clear that there was no 
interference from dissolution medium in the absorption 
spectrum of OXC at the wavelength of 305 nm, or the 
spectral profile from 200 to 400 nm.
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The method demonstrated to be linear in the con-
centration ranges of 10-90 µg/ml (SLS 0.5% w/v) and 
30-90 µg/mL (SLS 1.0% w/v) and all correlation coeffi-
cients (r) were over 0.999. The linear regression equa-
tion was y = 0.0093x – 0.0079 for SLS 0.5% w/v and 
y = 0.0091x – 0.0046 for SLS 1.0% w/v. Beer’s law is 
obeyed over this concentration range. 
Based on FDA recommendations for water insoluble 
or sparingly water soluble drug products, use of a surfac-
tant such as sodium lauryl sulfate is recommended where 
the surfactant should be used in the smallest possible 
amount (FDA, 1997). OXC is a sparingly water soluble 
drug and physiological variations in pH have no effect on 
its solubility (Flesch, 2004). Thus, the addition of LSS 
was necessary to enhance drug solubility. The experi-
mental results suggest that SLS 0.5% w/v yielded a better 
dissolution medium condition. Therefore, the optimum 
dissolution conditions were determined as follows: 0.5% 
SLS as dissolution medium, in baskets at a stirring speed 
of 100 rpm as apparatus and time of 30 min, tolerance of 
80%, and determination accomplished by spectrophoto-
metry at 305 nm. The average percent release of OXC in 
30 and 60 minutes, from the three formulations is shown 
in Table VII.
Statistical methods based on the analysis of variance 
(ANOVA) and Tukey’s test were used to compare the re-
sults of the dissolution test after 30 and 60 minutes. There 
was no significant difference between the data obtained 
from Formulations 1-3 after 30 minutes (p > 0.05). In con-
trast, there was a significant difference between the rates 
of dissolution of Formulations 1 and 2 after 60 minutes 
(p < 0.05). Typical acceptance criteria for the amount of 
drug dissolved lie in the range of 85% dissolved after 30 
minutes (FDA, 1997). All formulations presented more 
than 85% of OXC dissolved in 30 minutes.
OXC capsules are dosage forms for immediate re-
lease and therefore the tested formulations were adequate 
for this purpose. 
Table VII - Mean percent drug release from the three formulations 
in SLS 0.5% (w/v) dissolution medium
Formulations % Drug release (R.S.D.%, n = 6) 
SLS 0.5% 100 rpm
30 min 60 min
1 86.73 (4.85) 86.78 (4.89)
2 89.68 (13.72) 94.41 (5.82)
3 92.44 (7.57) 92.49 (4.07)
CONCLUSIONS
In conclusion, the UV spectrophotometric method 
described in the present study has been shown to be ac-
curate, sensitive, precise, rapid and easy to perform. In 
addition, the proposed method can be applied to the quality 
control analysis of OXC without interferences from the 
excipients normally used in capsule formulations. The 
method was successfully applied to analyze OXC in three 
developed formulations.
The dissolution test developed and validated for 
OXC capsules was considered satisfactory and can be used 
for quality control and pharmacotechnical development 
purposes. Rapid drug release was obtained from the three 
tested formulations.
Among the formulations tested, Formulation 2 was 
the best in terms of drug-excipient compatibility. In addi-
tion, Formulation 2 showed sufficient flowability to ensure 
uniform filling of capsules and a good dissolution profile.
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